[1] 高晓倩,于华惠,刘圣,等.血尿素氮水平对急性冠状动脉综合征患者PCI术后MACE的预测价值[J].基础医学与临床,2024,44:606-612. [2] Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeuticintervention[J]. Signal Transduct Target Ther, 2022,22,7:131. doi: 10.1038/s41392-022-00955-7. [3] Willems R, Pil L, Lambrinou CP, et al. Feel4 diabetes research group. methodology of the health economic evaluation of the Feel4 diabetes-study[J]. BMC Endocr Disord, 2020,12,20:14. doi: 10.1186/s12902-019-0471-3. [4] Shin MA, Oh S, Kim MC, et al. Time to presentation and mortality outcomes among patients with diabetes and acute myocardial infarction[J]. Korean J Intern Med, 2024,39:110-122. [5] Abdolalian M, Khalaf-Adeli E, Yari F, et al. Correlations between the circulating level of cell-derived microparticles and surgical variables in heart valve surgery with cardiopulmonary bypass[J]. J Tehran Heart Cent, 2022,17:134-139. [6] Han WQ, Chang FJ, Wang QR, et al. Microparticles from patients with the acute coronary syndrome impair vasodilatation by inhibiting the Akt/eNOS-Hsp90 signaling pathway[J]. Cardiology, 2015,132: 252-60. [7] Cheng G, Shan XF, Wang XL, et al. Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways[J]. Cardiovasc Ther, 2017, 35. doi: 10.1111/1755-5922.12273. [8] Li Z, Zhang W, Wang QR, et al. Effect of thrombolysis on circulating microparticles in patients with ST-segment elevation myocardial infarction[J]. Cardiovasc Ther, 2023,2023:5559368. doi: 10.1155/2023/5559368. [9] Biasucci LM, Porto I, Di Vito L, et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina[J]. Circ J, 2012,76:2174-2182. [10] Bernal-Mizrachi L, Jy W, Fierro C, et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes[J]. Int J Cardiol, 2004,97:439-446. [11] 余姿漫,赵炳佳,杨丹.JAK-STAT信号通路与糖尿病并发症的研究进展[J].基础医学与临床,2023,43:1590-1593. [12] Mannar V, Boro H, Patel D, et al. Epigenetics of the pathogenesis and complications of type 2 diabetes mellitus[J]. touchREV Endocrinol, 2023,19:46-53. [13] Mineo C, Shaul PW. Regulation of eNOS in caveolae[J]. Adv Exp Med Biol, 2012,729:51-62. [14] Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice[J]. Proc Natl Acad Sci U S A, 2002,99:11375- 11380. [15] Petrova NV, Tarasov SA, Epstein OI, et al. Highly diluted antibodies to eNOS restore endothelium function in aortic rings from hypertensive rats[J]. Dose Response, 2022,20:1559325822 1099281. doi: 10.1177/15593258221099281. |